Over the past three years, Eli Lilly's guidance has trailed its own demand almost every quarter, raising its outlook repeatedly while the two moments that looked like real setbacks — a 2024 guidance trim and a 2025 pharmacy-benefit-manager snub — both resolved within months and became springboards for the next increase.
The story
Late 2023: still in the "planting" phase
In November 2023 (the Q3 call), Lilly was on the verge of launching Zepbound (that December), while Mounjaro was still in its early penetration phase. The 2023 numbers themselves weren't glamorous—revenue grew 20% but net income actually fell 16%, reflecting heavy spending on new manufacturing capacity and acquired drug assets (IPR&D). When the company issued its first 2024 revenue guidance in February 2024, at $40.4–41.6 billion (about 30% growth), it was ambitious but still just a promise.
The turning point: demand outrunning the company's own forecasts
What happened next was that Mounjaro and Zepbound demand kept beating the company's own expectations. Guidance was raised in Q1 2024 (to $42.4–43.6B) and again in Q2 (to $45.4–46.6B), and by the Q3 call management used the word "accelerating" twelve times — confidence at its peak. But that same call revealed the first crack: guidance's top end was actually lowered, from $46.6B to $46.0B. Management explained, "this is the driver for lowering the top end of the range," attributing it to deliberately pacing demand-generation activity to match supply — in other words, a happy kind of bottleneck: the potential to sell was outrunning the ability to manufacture.
The response: broadening the risk language, then a real scare
Through this period, filing language shifted subtly. The FY2024 10-K introduced the phrase "patient access issues" as a risk factor for the first time, and broadened the language describing revenue concentration from "GLP-1 products" to the wider "cardiometabolic health products." Then, on April 30, 2025, news broke the same morning as earnings that CVS Caremark had chosen rival Wegovy over Zepbound as its preferred formulary drug. Analysts pressed management on this repeatedly—heavily on the Q1 call, five times on Q2, twice more on Q3—the same question recurring across three straight quarters is itself a signal the market wasn't fully convinced by the company's answers. That quarter's guidance was, for the first time in two years, held flat rather than raised.
Where it stands now
Questions about the CVS issue faded quickly after Q3 (down to zero by Q4), and that same Q3 call brought a string of positive Phase 3 data readouts for orforglipron (the oral obesity pill), prompting another guidance raise to $63–63.5B. Actual 2025 revenue landed at $65.2 billion, beating even that final raised range. The 2026 guidance opened with a striking framing—"$15–20 billion higher than 2025"—starting at $80–83B, then raised twice more over the following two quarters (to $82–85B, then $85–87B), the familiar pattern repeating itself. At the same time, the FY2025 10-K named China as a competitor for the first time, and added the explicit disclosure that "Mounjaro and Zepbound accounted for 56 percent of our total revenues" — the company is increasingly aware of, and disclosing, its own concentration.
Guidance vs. actual results
| Point in time | Revenue guidance | Action |
|---|---|---|
| FY2024 · Q4'23 call (Feb. 2024) | $40.4–41.6B | Initial |
| FY2024 · Q1'24 call | $42.4–43.6B | Raised |
| FY2024 · Q2'24 call | $45.4–46.6B | Raised |
| FY2024 · Q3'24 call | $45.4–46.0B | Top end trimmed |
| FY2024 actual | $45.04B | $4.0B above the original guidance |
| FY2025 · Q4'24 call (Feb. 2025) | $58–61B | Initial |
| FY2025 · Q1'25 call | $58–61B | Held flat (right after the CVS news) |
| FY2025 · Q2'25 call | $60–62B | Raised |
| FY2025 · Q3'25 call | $63–63.5B | Raised |
| FY2025 actual | $65.18B | Above even the final raised range |
| FY2026 · Q4'25 call (Feb. 2026) | $80–83B | Initial ("$15–20B higher than 2025") |
| FY2026 · Q1'26 call | $82–85B | Raised |
| FY2026 · Q2'26 call (latest) | $85–87B | Raised, in progress |
Source: earnings-call transcripts, Q3 FY2023 through Q2 FY2026; actual results from 10-K FY2024 and FY2025.
Both of the last two completed fiscal years (2024 and 2025) ended above even the final raised guidance — a 2-for-2 track record. The clear pattern is chronic under-promising: start conservative, then raise repeatedly. The only exceptions were the single top-end trim in Q3 2024 and the single flat hold in Q1 2025 — both of which turned out to be pauses, not reversals.
Timeline
- Nov. 2023Zepbound approaching launch (December); 2023 net income actually falls 16% on heavy capacity and IPR&D investment.
- Feb. 2024Initial FY2024 guidance issued at $40.4–41.6B.
- H1 2024Guidance raised twice as Mounjaro/Zepbound demand outpaces the company's own forecasts.
- Q3 2024 call"Accelerating" used 12 times, yet guidance's top end is trimmed for the only time in the period — a deliberate supply/demand pacing decision, not weak demand.
- FY2024 10-K"Patient access issues" appears as a new risk factor for the first time.
- Apr. 30, 2025CVS Caremark chooses Wegovy over Zepbound as preferred formulary drug, breaking the same morning as Q1 earnings; guidance held flat rather than raised for the first time in two years.
- Q3 2025 callCVS-related analyst questions fade; positive orforglipron Phase 3 data drives a guidance raise to $63–63.5B.
- FY2025 10-K (Feb. 2026)China named as a competitor for the first time; "Mounjaro and Zepbound accounted for 56 percent of our total revenues" disclosed explicitly.
- Feb.–Jul. 2026FY2026 guidance raised twice, from an initial $80–83B to $85–87B.
Our read
The last two to three years read less like a story of struggling to find demand and more like a story of struggling to keep up with too much of it. The two moments that looked like cracks — the Q3 2024 guidance trim and the 2025 CVS formulary loss — both resolved within a few months and became launching pads for the next raise rather than lasting setbacks. The real question for the next two to three years is whether this pattern continues, or whether depending on two products for 56% of revenue eventually becomes the boomerang — through intensified competition, drug-pricing policy, or litigation.
What we still don't know
- Whether the "always raise" pattern continues past Q3 2026 isn't yet confirmed, since results for that period haven't been reported.
- Which specific companies or pipelines the newly named "China" competitive risk refers to can't be identified from the risk-factor language alone.
- How precisely orforglipron's actual U.S. launch timing and pricing are baked into 2026-and-beyond guidance requires checking upcoming earnings calls.
Frequently asked questions
Has Eli Lilly ever missed its own guidance?
No — in both of the last two completed fiscal years (2024 and 2025), actual results exceeded even the final, most-raised version of the company's own guidance. The only exceptions were a single guidance-ceiling trim in Q3 2024 and a single flat hold in Q1 2025, both of which resolved within a few months.
What was the CVS Caremark issue in 2025?
On April 30, 2025, the same morning as Q1 earnings, CVS Caremark announced it had chosen rival drug Wegovy over Lilly's Zepbound as its preferred formulary option. Analysts asked about it on three consecutive quarterly calls before the concern faded by Q4 2025.
What sources does this analysis draw from?
This piece is built from Eli Lilly's 10-K filings for fiscal years 2023 through 2025 and twelve quarters of earnings-call transcripts spanning Q3 FY2023 through Q2 FY2026.